QUCY stock forecast, quote, news & analysis
Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity... Show more
Why Quantum Cyber N.V. (QUCY) Is Up +1.5% in the Last 30 Days
Key Takeaways
- QUCY experienced a modest +1.5% gain over the past 30 days amid high volatility, driven by strategic announcements including IP divestiture and cybersecurity pivot.
- Over the past quarter, the stock plunged -58%, reflecting uncertainty around the company's rebranding from biotech to quantum cybersecurity and Nasdaq compliance challenges.
- Key factors include low trading volume, Nasdaq bid price deficiency notice, $3 million funding infusion, and broader weakness in speculative biotech and emerging tech sectors.
- Recent news on refocusing on pancreatic screening and cyber defense acquisitions contributed to short-term stabilization.
- Market sentiment remains cautious due to penny stock dynamics and execution risks in the company's transformation.
Quantum Cyber N.V. (QUCY) Overview and Portfolio Exposure
Quantum Cyber N.V. (QUCY), formerly known as Mainz Biomed N.V., is a NASDAQ-listed company that has transitioned from developing molecular diagnostics for cancer detection to building a platform at the intersection of quantum computing and cybersecurity. Originally focused on in-vitro diagnostic tests like ColoAlert for colorectal cancer and PancAlert for pancreatic cancer, the company rebranded in March 2026 to prioritize quantum and cyber defense technologies aligned with U.S. national security priorities.
As a single-stock entity rather than a diversified ETF, QUCY has no traditional portfolio of holdings. Its value is tied directly to the company's assets, including approximately $6.24 million in cash and equivalents, intellectual property, and potential strategic acquisitions. Sector exposure has shifted from healthcare/biotechnology (100% previously) toward technology, specifically emerging quantum cybersecurity themes. This concentrated exposure amplifies price sensitivity to company-specific news, explaining the extreme volatility in recent performance.
Quantum Cyber N.V. (QUCY) Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, QUCY rose +1.5%, trading in a highly volatile, range-bound pattern from around $0.48 to peaks near $0.63 before settling at approximately $0.49. Daily swings exceeded 20% on several occasions, characteristic of low-float penny stocks.
In contrast, the past quarter saw a steep -58% decline, dropping from about $1.10 to $0.49. The movement was sharply trend-driven downward, punctuated by brief spikes around the March rebranding and funding news, but weighed by ongoing compliance issues and sector headwinds. Average daily volume hovered around 700,000 shares, indicating thin liquidity.
What Drove QUCY Price in the Last 30 Days
QUCY's slight uptick over the past 30 days stemmed from a mix of company catalysts and speculative trading. On April 15, the announcement of divesting its ColoAlert intellectual property (IP) allowed refocus on higher-potential pancreatic cancer screening and cyber initiatives, sparking intraday gains of over 20%. Earlier, a March 25 Nasdaq notice citing bid price deficiency (shares below $1 for 30 days) heightened delisting fears, pressuring prices downward.
A $3 million pre-funded investment from shareholder David Lazar in mid-March provided cash runway for acquisitions, bolstering sentiment temporarily. With no diversified holdings, price action mirrored these events directly. Broader market trends in speculative tech and biotech offered little support, as investor focus remained on execution amid the pivot. Trading volume spiked on news days, underscoring event-driven behavior.
What Drove QUCY Performance Over the Last Quarter
The quarter's -58% drop was fueled by uncertainty surrounding the March 12 ticker change and rebranding to Quantum Cyber, diluting prior biotech enthusiasm. Shares plummeted from $1.10 amid skepticism over the strategic shift from diagnostics to unproven quantum cybersecurity, with limited operational revenue (development-stage company).
Macro factors like elevated interest rates hampered risk appetite for micro-cap names, while biotech sector underperformance exacerbated losses. The Nasdaq compliance warning compounded pressure, as sustained sub-$1 trading triggered deficiency status. Positive offsets included the $3 million funding and acquisition pursuit announcements, but cumulative impact favored bears. Institutional flows were negligible given the $6 million market cap, leaving retail speculation dominant.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.
QUCY ETF Outlook: What Investors Should Watch Next
Investors should monitor Nasdaq compliance progress, particularly regaining a $1 bid price to avoid delisting risks. Key acquisition developments in quantum cybersecurity will be critical, alongside updates on PancAlert commercialization. Watch biotech sector trends and emerging tech sentiment amid macroeconomic shifts like interest rates and national security policy changes. Funding sustainability and cash burn rates warrant attention, as does trading volume for liquidity signals. Potential catalysts include partnership announcements, while risks involve execution delays in the strategic pivot.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
QUCY sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for QUCY moved above the 200-day moving average on June 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where QUCY advanced for three days, in of 173 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for QUCY moved out of overbought territory on May 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QUCY as a result. In of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for QUCY turned negative on June 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .
QUCY moved below its 50-day moving average on June 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QUCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. QUCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.675) is normal, around the industry mean (12.431). P/E Ratio (0.000) is within average values for comparable stocks, (145.825). QUCY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.482). QUCY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). QUCY's P/S Ratio (23.095) is slightly higher than the industry average of (7.245).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QUCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement